Characterization of the Analgesic Effect of CBD in Healthy, Normal Volunteers

• Status: Completed
• Trial end date: 2020-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this double-blind, placebo-controlled study is to determine the analgesic effects of cannabidiol (CBD), a chemical constituent found in cannabis that does not have intoxicating effects. The analgesic effects of CBD will be assessed using the Cold-Pressor Test (CPT), a laboratory model of pain which has predictive validity for the clinical use of analgesics.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: New York State Psychiatric Institute; University of California, Los Angeles
• Collaborator: INSYS Therapeutics Inc
• Treatments: Analgesics; Cannabidiol

Criteria

Inclusion Criteria:

• Able to perform study procedures

• Women practicing an effective form of birth control

Exclusion Criteria:

• Female subjects who are currently pregnant or breastfeeding.

• Current illicit drug use

• Presence of significant medical illness

• History of heart disease

• Request for drug treatment

• Current parole or probation

• Recent history of significant violent behavior

• Major psychiatric disorder

• Current use of any prescription or over-the-counter medication

• Current pain

• Clinically significant Raynaud's syndrome